Homologous recombination-based adenovirus vector system for tumor cell-specific gene delivery

References

• Alemany R. Designing adenoviral vectors for tumor-specific targeting. Methods Mol Biol 2009; 542:57 - 74; http://dx.doi.org/10.1007/978-1-59745-561-9_2; PMID: 19565895
   PubMedGoogle Scholar
• Oum YH, Carrico IS. Altering adenoviral tropism via click modification with ErbB specific ligands. Bioconjug Chem 2012; 23:1370 - 6; http://dx.doi.org/10.1021/bc200477z; PMID: 22681483
   PubMed Web of Science ®Google Scholar
• Banerjee PS, Ostapchuk P, Hearing P, Carrico IS. Unnatural amino acid incorporation onto adenoviral (Ad) coat proteins facilitates chemoselective modification and retargeting of Ad type 5 vectors. J Virol 2011; 85:7546 - 54; http://dx.doi.org/10.1128/JVI.00118-11; PMID: 21613404
   PubMed Web of Science ®Google Scholar
• Zhang KJ, Zhang J, Wu YM, Qian J, Liu XJ, Yan LC, et al. Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression. Cancer Gene Ther 2012; 19:619 - 29; http://dx.doi.org/10.1038/cgt.2012.40; PMID: 22790965
   PubMed Web of Science ®Google Scholar
• Fontecedro AC, Lutschg V, Eichhoff O, Dummer R, Greber UF, Hemmi S. Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro. Virol J 2010; 7:175; http://dx.doi.org/10.1186/1743-422X-7-175; PMID: 20670430
   PubMed Web of Science ®Google Scholar
• Pouliot F, Karanikolas BD, Johnson M, Sato M, Priceman SJ, Stout D, et al. In vivo imaging of intraprostatic-specific gene transcription by PET. J Nucl Med 2011; 52:784 - 91; http://dx.doi.org/10.2967/jnumed.110.084582; PMID: 21498525
   PubMed Web of Science ®Google Scholar
• Subramanian T, Vijayalingam S, Chinnadurai G. Genetic identification of adenovirus type 5 genes that influence viral spread. J Virol 2006; 80:2000 - 12; http://dx.doi.org/10.1128/JVI.80.4.2000-2012.2006; PMID: 16439556
   PubMed Web of Science ®Google Scholar
• Stone D. Novel viral vector systems for gene therapy. Viruses 2010; 2:1002 - 7; http://dx.doi.org/10.3390/v2041002; PMID: 21994667
   PubMed Web of Science ®Google Scholar
• Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008; 6:529 - 40; http://dx.doi.org/10.1038/nrmicro1927; PMID: 18552863
   PubMed Web of Science ®Google Scholar
• Zheng X, Rao XM, Gomez-Gutierrez JG, Hao H, McMasters KM, Zhou HS. Adenovirus E1B55K region is required to enhance cyclin E expression for efficient viral DNA replication. J Virol 2008; 82:3415 - 27; http://dx.doi.org/10.1128/JVI.01708-07; PMID: 18234796
   PubMed Web of Science ®Google Scholar
• Kühnel F, Gürlevik E, Wirth TC, Strüver N, Malek NP, Müller-Schilling M, et al. Targeting of p53-transcriptional dysfunction by conditionally replicating adenovirus is not limited by p53-homologues. Mol Ther 2010; 18:936 - 46; http://dx.doi.org/10.1038/mt.2009.298; PMID: 20040911
   PubMed Web of Science ®Google Scholar
• Yun CO, Kim E, Koo T, Kim H, Lee YS, Kim JH. ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis. Cancer Gene Ther 2005; 12:61 - 71; http://dx.doi.org/10.1038/sj.cgt.7700769; PMID: 15375379
   PubMed Web of Science ®Google Scholar
• Liu Y, Tuve S, Persson J, Beyer I, Yumul R, Li ZY, et al. Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models. Cancer Gene Ther 2011; 18:407 - 18; http://dx.doi.org/10.1038/cgt.2011.8; PMID: 21394107
   PubMed Web of Science ®Google Scholar
• Bernt K, Liang M, Ye X, Ni S, Li ZY, Ye SL, et al. A new type of adenovirus vector that utilizes homologous recombination to achieve tumor-specific replication. J Virol 2002; 76:10994 - 1002; http://dx.doi.org/10.1128/JVI.76.21.10994-11002.2002; PMID: 12368342
   PubMed Web of Science ®Google Scholar
• Bernt KM, Ni S, Tieu AT, Lieber A. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Cancer Res 2005; 65:4343 - 52; http://dx.doi.org/10.1158/0008-5472.CAN-04-3527; PMID: 15899826
   PubMed Web of Science ®Google Scholar
• Glockzin G, Mantwill K, Jurchott K, Bernshausen A, Ladhoff A, Royer HD, et al. Characterization of the recombinant adenovirus vector AdYB-1: implications for oncolytic vector development. J Virol 2006; 80:3904 - 11; http://dx.doi.org/10.1128/JVI.80.8.3904-3911.2006; PMID: 16571807
   PubMed Web of Science ®Google Scholar
• Loewenstein PM, Wu SY, Chiang CM, Green M. The adenovirus E1A N-terminal repression domain represses transcription from a chromatin template in vitro. Virology 2012; 428:70 - 5; http://dx.doi.org/10.1016/j.virol.2012.03.021; PMID: 22521914
   PubMed Web of Science ®Google Scholar
• Su JL, Cheng X, Yamaguchi H, Chang YW, Hou CF, Lee DF, et al. FOXO3a-dependent mechanism of E1A-induced chemosensitization. Cancer Res 2011; 71:6878 - 87; http://dx.doi.org/10.1158/0008-5472.CAN-11-0295; PMID: 21911455
   PubMed Web of Science ®Google Scholar
• Loewenstein PM, Green M. Expression of the adenovirus early gene 1A transcription-repression domain alone downregulates HER2 and results in the death of human breast cancer cells upregulated for the HER2 proto-oncogene. Genes Cancer 2011; 2:737 - 44; http://dx.doi.org/10.1177/1947601911426570; PMID: 22207899
   PubMedGoogle Scholar
• Chakraborty AA, Tansey WP. Adenoviral E1A function through Myc. Cancer Res 2009; 69:6 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-08-3026; PMID: 19117980
   PubMed Web of Science ®Google Scholar
• Gomez-Gutierrez JG, Rao XM, Zhou HS, McMasters KM. Enhanced cancer cell killing by truncated E2F-1 used in combination with oncolytic adenovirus. Virology 2012; 433:538 - 47; http://dx.doi.org/10.1016/j.virol.2012.09.003; PMID: 23021422
   PubMed Web of Science ®Google Scholar
• Halldén G, Portella G. Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets. Expert Opin Ther Targets 2012; 16:945 - 58; http://dx.doi.org/10.1517/14728222.2012.712962; PMID: 22880939
   PubMed Web of Science ®Google Scholar
• Fukazawa T, Matsuoka J, Yamatsuji T, Maeda Y, Durbin ML, Naomoto Y. Adenovirus-mediated cancer gene therapy and virotherapy (Review). Int J Mol Med 2010; 25:3 - 10; PMID: 19956895
   PubMed Web of Science ®Google Scholar
• Hedjran F, Shantanu K, Tony R. Deletion analysis of Ad5 E1a transcriptional control region: impact on tumor-selective expression of E1a and E1b. Cancer Gene Ther 2011; 18:717 - 23; http://dx.doi.org/10.1038/cgt.2011.41; PMID: 21818136
   PubMed Web of Science ®Google Scholar
• Ohtani S, Kagawa S, Tango Y, Umeoka T, Tokunaga N, Tsunemitsu Y, et al. Quantitative analysis of p53-targeted gene expression and visualization of p53 transcriptional activity following intratumoral administration of adenoviral p53 in vivo. Mol Cancer Ther 2004; 3:93 - 100; PMID: 14749479
   PubMed Web of Science ®Google Scholar
• Ye X, Lu Q, Zhao Y, Ren Z, Ren XW, Qiu QH, et al. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma. Int J Mol Med 2005; 16:1179 - 84; PMID: 16273304
   PubMed Web of Science ®Google Scholar
• Lu Q, Yu DH, Fang C, Liu F, Ye X, Zhao Y, et al. Influence of E3 region on conditionally replicative adenovirus mediated cytotoxicity in hepatocellular carcinoma cells. Cancer Biol Ther 2009; 8:1125 - 32; http://dx.doi.org/10.4161/cbt.8.12.8445; PMID: 19448394
   PubMed Web of Science ®Google Scholar